The true impact is starting to be felt.

GLP-1 EVENTS REPORTED

More than 60 deaths have been reported to Australia’s medicines regulator in cases where popular GLP-1 weight-loss drugs were suspected of being involved, prompting renewed scrutiny of the rapidly expanding use of the medicines.

Data from the Therapeutic Goods Administration (TGA), compiled on 7 August 2026, recorded 62 reports of deaths potentially associated with four medicines in the GLP-1 class, according to an investigation published in August.

The reports involved semaglutide, sold as Ozempic and Wegovy; tirzepatide, sold as Mounjaro; liraglutide, sold as Saxenda; and dulaglutide, sold as Trulicity.

Semaglutide accounted for the largest number, with 37 reported deaths, followed by liraglutide with 11, tirzepatide with nine, and dulaglutide with five.

The TGA also recorded 2,829 adverse event reports involving the medicines, including serious gastrointestinal problems, pancreatitis, and reports of suicidal thoughts.

The figures have attracted attention because GLP-1 medicines have moved rapidly from being primarily diabetes treatments to becoming mainstream weight-loss drugs.

Hundreds of thousands of Australians are now estimated to be using weight-loss medicines, reflecting the extraordinary growth in demand for treatments.

What is interesting is that the TGA has stressed the figures do not establish that the medicines caused the deaths – and other factors such as obesity, diabetes, or cardiovascular disease could independently contribute to serious illness or death.

I find it funny how co-morbidities suddenly matter when it comes to the ‘treatment’ offered, but not for fearmongering for the disease.

For example, their philosophy is: COVID certainly killed everyone (no other causes), but the jab for COVID killed nobody (all due to other causes). A calculated narrative.

One GLP-1 weight-loss case that has highlighted this new issue is that of South Australian truck driver, Tim Ramsay, who died 19 days after beginning Saxenda treatment.

He developed a number of symptoms before his death, but the coroner recorded the cause as “undetermined” and referred the case to the TGA as part of medicines-safety monitoring.

His daughter has continued to question whether the drug contributed to his death.

The scrutiny comes amid a wider series of safety concerns surrounding the medicines.

The TGA has already warned about counterfeit weight-loss products claiming to contain GLP-1 drugs, some of which have been sold outside the normal supply chain.

They have also updated warnings concerning non-arteritic anterior ischaemic optic neuropathy (NAION), a rare eye disorder that can cause sudden loss of vision.

Cases have been reported in people taking several GLP-1 medicines, including semaglutide, liraglutide, dulaglutide, and tirzepatide.

Doctors and dietitians have consequently called for greater safeguards around prescribing, particularly through telehealth services.

Some are concerned that the ease with which people can obtain weight-loss medicines may reduce opportunities for medical assessment, nutritional advice, and effect monitoring.

As we know, underreporting is also a giant scandal surrounding TGA data released – meaning we also don’t know the true extent of the damage being done by these drugs.

Despite the concerns, GLP-1 medicines remain as popular ‘treatments’ for type 2 diabetes and obesity – growing in usage rates each and every year.

The public figures alone should stress the importance of monitoring medicines before taking them, as the pharma-doctor-industrial complex has no regard for your safety.

This is the latest product to come packaged and delivered to a public brainwashed by modern beauty standards – looking to shred a few kilograms the Big Pharma way.

Like opioids, vaccines, and other ‘remedies’, we are now starting to see the bodies pile up.

How can people still continue to trust these snakes?

WEIGHT-LOSS HYSTERIA

From what once started as a fad among celebrities, has quickly taken over much of the Western world – as weight-loss drugs become the ‘go to’ for those looking to keep slim.

Today, around 420,000 Australians are using either semaglutide or tirzepatide through private prescriptions, according to the latest data.

It has become so widespread that the mad scientists are moving to target children next.

Researchers are currently investigating whether GLP-1 weight-loss medicines could ‘help’ kids with obesity ‘become healthier’ – but the prospect of treating younger patients has raised questions about the safety and long-term effects of such a radical plan.

Eli Lilly is also studying newer medicines, including tirzepatide, in younger populations. Early research is examining ‘safety’ and how children’s bodies respond to the treatment.

Many are concerned about the limited information available on the effects of long-term treatment during important stages of growth and development.

A child starting medication at six years old could potentially take it for many years, making long-term safety a major consideration.

Others have questioned whether expanding access to weight-loss medicines could place too much emphasis on medication, rather than addressing wider causes of childhood obesity, including food environments, poverty, sleep patterns, and access to healthy lifestyles.

This rise in popularity has also forced the food industry to change their approach.

As we know, Big Food has spent decades engineering products to keep people eating.

Now, with millions turning to weight-loss drugs like Ozempic, the industry faces a crisis: customers who simply don’t crave their products anymore.

Patients on popular weight loss drugs have reported losing interest in eating ultraprocessed junk, as the food industry looks to combat this new emerging threat.

Big Pharma vs Big Food: The Battle for Your Appetite
RELATED VIDEO

So, what are they doing to navigate this shift?

Companies like Nestlé are introducing product lines such as Vital Pursuit, a new category of foods intended to be a “companion” for GLP-1 weight loss medication users.

This type of move by Nestlé perfectly highlights just how widespread use of these products has become, with more people falling for the propaganda each year that passes.

No doubt, as the statistics continue to climb, so too will those in the adverse events column.

What are your thoughts on this latest data? Are you surprised?

Be sure to leave your thoughts in the comment section below!

KEEP UP-TO-DATE

For more TOTT News:

Facebook — Facebook.com/TOTTNews

YouTube — YouTube.com/TOTTNews

Instagram — Instagram.com/TOTTNews

Twitter — Twitter.com/EthanTOTT

Rumble — Rumble.com/c/TOTTNews

Bitchute — Bitchute.com/TOTTNews

Gab — Gab.com/TOTTNews